Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 9/20 | 0.41 |
| ▸ | MMP1 | P03956 | 7/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.41 |
| ▸ | MMP3 | P08254 | 6/20 | 0.40 |
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451733 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBMMP9 | |
| SCHEMBL85933 | 0.89 | MMP9 (0.43) | SMN1; SMN2MEN1KMT2AMMP9MMP1 | |
| SCHEMBL8213580 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2APOLBMMP9 | |
| SCHEMBL5581114 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2APOLBMMP9 | |
| SCHEMBL10820749 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL2568385 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL2822724 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL6207847 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL2567250 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBLMNA | |
| SCHEMBL2827980 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109698-A1 | MALT-1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2026-04-23 | — | — | US | disclosed |
| US-20250074876-A1 | DIPHENOLIC COMPOUNDS AND PREPARATION METHODS THEREOF | PURPANA (BEIJING) TECHNOLOGIES CO., LTD. (CN) | 2025-03-06 | — | — | US | disclosed |
| US-20250051327-A1 | MALT-1 MODULATORS | RECURSION PHARMACEUTICALS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024147125-A1 | CYCLOBUTYL-SUBSTITUTED PHENOXY-DIOXETANES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-07-11 | — | — | WO | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9512115-B2 | Inhibitors | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9462793-B2 | Mouse carrying a knock-out mutation of the Qpct-gene | PROBIODRUG AG (DE) | 2016-10-11 | — | — | US | disclosed |
| US-9345662-B2 | Degradable hydrogel compositions and methods | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | disclosed |
| US-7244752-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-17 | — | — | US | disclosed |
| US-7244752-B2 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-17 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | SURLERAUX DOMINIQUE LOUIS N G | 2007-06-14 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | SMN1; SMN2 4257/4885MEN1 4487/4885KMT2A 3778/4885 |
| US-20250074876-A1 | DIPHENOLIC COMPOUNDS AND PREPARATION METHODS THEREOF | HRH1, HRH3, HRH4 | SMN1; SMN2 4723/4885MEN1 943/4885KMT2A 1077/4885 |
| US-20250051327-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL9 | SMN1; SMN2 2943/4885MEN1 1664/4885KMT2A 2155/4885 |
| US-20070135447-A1 | N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication | NR0B1, NR0B2, NR2C2 | SMN1; SMN2 1485/4885MEN1 2911/4885KMT2A 1422/4885 |
| US-20260109698-A1 | MALT-1 MODULATORS | MALT1, BCL6, BCL3 | SMN1; SMN2 2386/4885MEN1 2473/4885KMT2A 2982/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | SMN1; SMN2 3960/4885MEN1 3455/4885KMT2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.